硝苯地平的经肝提取率。
The trans-hepatic extraction of nifedipine.
作者信息
Challenor V F, Waller D G, Renwick A G, Gruchy B S, George C F
机构信息
Clinical Pharmacology Group, University of Southampton.
出版信息
Br J Clin Pharmacol. 1987 Oct;24(4):473-7. doi: 10.1111/j.1365-2125.1987.tb03200.x.
Abstract
- The trans-hepatic extraction of nifedipine during steady state infusion was studied in six patients undergoing cardiac catheterisation for suspected coronary disease. 2. Mean extraction ratio across the liver was 0.64 but hepatic clearance accounted for a mean of only 65% of total body clearance. 3. These results are consistent with the liver as the major site of metabolism of nifedipine, but also suggest that significant metabolism occurs outside the liver.
摘要
- 在6名因疑似冠心病接受心导管检查的患者中，研究了稳态输注期间硝苯地平的经肝提取情况。2. 肝脏的平均提取率为0.64，但肝清除率平均仅占全身清除率的65%。3. 这些结果与硝苯地平以肝脏为主要代谢部位一致，但也表明肝脏外存在显著的代谢。
相似文献
1
The trans-hepatic extraction of nifedipine.硝苯地平的经肝提取率。
Br J Clin Pharmacol. 1987 Oct;24(4):473-7. doi: 10.1111/j.1365-2125.1987.tb03200.x.
2
The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.维拉帕米和硝苯地平对乙肝表面抗原阳性肝硬化腹水患者肝脏吲哚菁绿清除率的影响。
Clin Pharmacol Ther. 1988 Oct;44(4):453-7. doi: 10.1038/clpt.1988.179.
3
Extrahepatic first-pass metabolism of nifedipine in the rat.硝苯地平在大鼠体内的肝外首过代谢
Biopharm Drug Dispos. 1997 Aug;18(6):509-22. doi: 10.1002/(sici)1099-081x(199708)18:6<509::aid-bdd38>3.0.co;2-5.
4
[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
Gastroenterol J. 1991;51(1):33-6.
5
Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine.大鼠肺代谢对利多卡因、咪达唑仑和硝苯地平消除的贡献。
Drug Metab Dispos. 2010 Jul;38(7):1183-8. doi: 10.1124/dmd.110.032227. Epub 2010 Apr 6.
6
Intravenous nifedipine for prevention of myocardial ischaemia after coronary revascularization.
Can J Anaesth. 1992 Dec;39(10):1012-22. doi: 10.1007/BF03008368.
7
Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.硝苯地平、维拉帕米和地尔硫䓬治疗期间安替比林和吲哚菁绿动力学的变化。
Clin Pharmacol Ther. 1986 Aug;40(2):239-42. doi: 10.1038/clpt.1986.169.
8
9
Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes.硝苯地平与二甲双胍在大鼠体内的药代动力学和药效学相互作用：二者通过细胞色素P450同工酶相互竞争抑制对方的代谢。
Xenobiotica. 2012 May;42(5):483-95. doi: 10.3109/00498254.2011.633177. Epub 2012 Mar 14.
10
引用本文的文献
1
The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.硝苯地平胃肠道治疗系统（GITS）。药物、药代动力学和药理学特性评估。
Clin Pharmacokinet. 1996 Jan;30(1):28-51. doi: 10.2165/00003088-199630010-00003.
2
Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects.健康受试者中葡萄柚汁摄入时间与其对非洛地平药代动力学和药效学影响的关系。
Eur J Clin Pharmacol. 1995;49(1-2):61-7. doi: 10.1007/BF00192360.
3
Lack of presystemic metabolism of nifedipine in the rabbit.硝苯地平在兔体内不存在首过代谢。
J Pharmacokinet Biopharm. 1995 Dec;23(6):567-80. doi: 10.1007/BF02353462.
4
Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.硝苯地平动力学的种族差异：尼日利亚人、白种人和南亚人之间的比较。
Br J Clin Pharmacol. 1995 Nov;40(5):489-93.
5
Factors affecting the absolute bioavailability of nifedipine.影响硝苯地平绝对生物利用度的因素。
Br J Clin Pharmacol. 1995 Jul;40(1):51-8. doi: 10.1111/j.1365-2125.1995.tb04534.x.
6
Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.健康受试者口服非洛地平和尼群地平的立体选择性药代动力学：与硝苯地平药代动力学的相关性
Eur J Clin Pharmacol. 1993;44(2):163-9. doi: 10.1007/BF00315475.
7
Clinical significance of genetic influences on cardiovascular drug metabolism.基因对心血管药物代谢影响的临床意义。
Cardiovasc Drugs Ther. 1993 Jun;7(3):311-24. doi: 10.1007/BF00880154.
8
Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment.硝苯地平控释片在慢性肾功能损害高血压患者中的药代动力学特征。
Drugs. 1994;48 Suppl 1:16-21; discussion 21-2. doi: 10.2165/00003495-199400481-00006.
9
Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.硝苯地平药代动力学和药效学的年龄相关性变化。
Br J Clin Pharmacol. 1988 Mar;25(3):297-305. doi: 10.1111/j.1365-2125.1988.tb03307.x.
10
The pharmacokinetics of oral nifedipine--a population study.口服硝苯地平的药代动力学——一项群体研究。
Br J Clin Pharmacol. 1988 Jun;25(6):701-8. doi: 10.1111/j.1365-2125.1988.tb05256.x.
本文引用的文献
1
Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.硝苯地平在正常受试者单次静脉注射和口服后的动力学及生物利用度。
J Clin Pharmacol. 1983 Apr;23(4):161-70. doi: 10.1002/j.1552-4604.1983.tb02720.x.
2
Clearance and non-invasive determination of the hepatic extraction of indocyanine green in baboons and man.狒狒和人类中吲哚菁绿肝摄取的清除率及非侵入性测定
Clin Sci (Lond). 1983 Feb;64(2):207-12. doi: 10.1042/cs0640207.
3
Nifedipine plasma concentration in patients treated for angina pectoris.接受心绞痛治疗患者的硝苯地平血浆浓度。
Int J Clin Pharmacol Ther Toxicol. 1984 Apr;22(4):198-203.
4
The first pass metabolism of nifedipine in man.硝苯地平在人体中的首过代谢。
Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
5
Cytochrome P-450-dependent oxidation of felodipine--a 1,4-dihydropyridine--to the corresponding pyridine.
Xenobiotica. 1984 Sep;14(9):719-26. doi: 10.3109/00498258409151470.
6
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.
Biochem Pharmacol. 1984 Nov 15;33(22):3721-4. doi: 10.1016/0006-2952(84)90165-5.
7
Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects.硝苯地平可增加正常受试者的肝脏表观血流量，而硝酸甘油则使其降低。
Br J Clin Pharmacol. 1984 Jan;17(1):83-5. doi: 10.1111/j.1365-2125.1984.tb05003.x.
8
Oxidation of 1,4-dihydropyridines by prostaglandin synthase and the peroxidic function of cytochrome P-450. Demonstration of a free radical intermediate.
Biochem Pharmacol. 1986 May 1;35(9):1419-25. doi: 10.1016/0006-2952(86)90105-x.
Zotero 插件